Market Place
Sourcing Support
Innate Pharma: Positive Phase 2 Lacutamab Data In Mycosis Fungoides
04 Jun 2024 //
BUSINESSWIRE
Innate Pharma Announces U.S. FDA Lifts Partial Hold on Lacutamab Program
04 Jan 2024 //
BUSINESSWIRE
Innate Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab
10 Dec 2023 //
BUSINESSWIRE
Innate Pharma Announces Presentation of Interim Results of Ph 2 TELLOMAK Study
22 Sep 2023 //
BUSINESSWIRE
Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab
12 Jun 2023 //
BUSINESSWIRE
Innate Present Data From PII TELLOMAK Trial Demonstrating Activity of Lacutamab
10 Dec 2022 //
BUSINESSWIRE
Innate Pharma reports data from Phase II mycosis fungoides antibody trial
26 Sep 2022 //
CLINICALTRIALSARENA
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial
23 Sep 2022 //
BUSINESSWIRE
Innate to Present Lacutamab PTCL Phase 1b Design & ANKET Platform at ESMO 2022
05 Sep 2022 //
BUSINESSWIRE
Innate Pharma reports first half 2021 financial results and business update
15 Sep 2021 //
GLOBENEWSWIRE
Innate Pharma Presents Preliminary Data from TELLOMAK Trial
22 Jun 2021 //
GLOBENEWSWIRE
Lacutamab Data to be Showcased at Malignant Lymphoma Conference
09 Jun 2021 //
GLOBENEWSWIRE
INNATE PHARMA RECEIVES PRIME DESIGNATION FROM THE EUROPEAN MEDICINES
12 Nov 2020 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.